Forskning ved Københavns Universitet - Københavns Universitet

Forside

Problemer med primakin-recidivprofylakse hos malariapatienter

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard treatment of P. ovale and P. vivax malaria is 1500 mg of chloroquine base given over three days followed by 15 mg of primaquine base daily for 14 days. At the Department of Infectious Diseases, Rigshospitalet, Copenhagen an increasing number of cases of relative by primaquine-resistant malaria have been observed. The side effects of primaquine are mainly gastrointestinal. Primaquine may also cause serious toxic side effects, including methaemoglobin formation and haemolytic anaemia, especially in individuals with erythrocyte glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. We present six patients who developed relapses of P. vivax after taking standard doses of primaquine. When increasing primaquine dosage, patients must be informed about the possibility of more severe side effects.
OriginalsprogDansk
TidsskriftUgeskrift for Laeger
Vol/bind155
Udgave nummer48
Sider (fra-til)3901-4
Antal sider4
ISSN0041-5782
StatusUdgivet - 29 nov. 1993

    Forskningsområder

  • Adult, Drug Resistance, Microbial, Gastrointestinal Diseases, Humans, Malaria, Falciparum, Malaria, Vivax, Male, Middle Aged, Primaquine, Recurrence

ID: 33890827